Back to the future: Antibody-based strategies for the treatment of infectious diseases

Oral H. B., Ozakin C., Akdis C.

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology, cilt.21, sa.3, ss.225-239, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 21 Sayı: 3
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1385/mb:21:3:225
  • Dergi Adı: Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.225-239
  • Anahtar Kelimeler: antibody therapy, infectious diseases, immunoglobulin, HUMAN-IMMUNODEFICIENCY-VIRUS, TUMOR-NECROSIS-FACTOR, HUMAN MONOCLONAL-ANTIBODY, PLACEBO-CONTROLLED TRIAL, INTRAVENOUS IMMUNOGLOBULIN THERAPY, BONE-MARROW TRANSPLANTATION, GRAM-NEGATIVE BACTEREMIA, B IMMUNE GLOBULIN, LIPID-A DOMAIN, SEPTIC SHOCK
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Before antibiotics, sera from immune animals and humans were used to treat a variety of infectious diseases, often with successful results. After the discovery of antimicrobial agents, serum therapy for bacterial infections was rapidly forsaken. In the last two decades, problems with treatment of newly emerged, reemerged, or persistent infectious diseases necessitated researchers to develop new and/or improved antibody-based therapeutic approaches. This article reviews some information on the use of antibodies for the treatment of infectious diseases, with special reference to the most seminal discoveries and current advances as well as available treatment approaches in this field.